Metabolic Dysfunction Associated Steatotic Liver Disease
10
3
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
Human Models of Selective Insulin Resistance: Pancreatic Clamp
Prognostic Model for MASLD Related Cirrhosis
Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Classification of MAFLD Based Liver Biopsy
COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study
Pattern of Cardiac Arrhythmia in Patients With MASLD
Investigating Myosteatosis in Steatotic Liver Diseases
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)